Cardiovascular disease is the important disease is harmful to human
health of China, one of the patients were admitted to the hospital every
year because of the disease in more than three thousand, die from the
disease has three million people, and every year on the rise. So, on the
cardiovascular disease diagnosis, treatment and rehabilitation has
become a cause global attention to the topic.
Recently, a clinical research: using NT-ProBNP assist in making the diagnosis congestive heart failure, the severity of the illness of the judgment and prognosis, and guide therapy has made the medical attention. It has been awarded as 2002 international medical ten big news, 2002 years is worth to pay close attention to ten big achievements of clinical medicine.
To date, there have been more than paper related research papers published in the New England journal of medicine (2002,347/3), circulation medical (2002105,-28), the American heart journal of (July 2002/2200 2-2009) other authoritative magazine. The paper discusses such as NT-ProBNP in heart failure emergency diagnosis function, rapid NT-ProBNP detection for difference of congestive heart failure or lung disease that causes breathing difficult problems, such as patients, for heart failure diagnosis and evaluation has opened up a whole new area.
N-end brain natriuretic peptide precursor is b-type natriuretic peptide hormones after the activity of the original split without the fragments N, mainly in the myocardial cells by load capacity increased by the left ventricular secretion, our company is mainly to a plant high specificity, high sensitivity NT-proBNP monoclonal antibodies for mark antibody, polyclonal antibody to capture antibody, combined with streptavidin-meal-biotin amplification system, the application of immune jinbiao chromatography technology. Detection of blood-proBNP NT, the content of which the patient diagnosis and screening, mainly is suitable for the instrument for nanjing perlong medical equipment Co., LTD. FIA8000 series immune quantitative analyzer.
My company product performance mainly for:
1, the double double control, and increase detecting window wide, and to improve the diagnostic value.
2, and some famous company of the same kind POCT products compare, the diagnosis window wide, price moderate, forgive by the domestic production line production, reliable quality, ensure that there is sufficient resources,
3, high sensitivity, the minimum detection is not higher than 100 pg/ml,
4, dose response curve of the linear correlation coefficient r > 0.990,
5, precision: of < 10%, within the CV of < 15%, between CV
6 and the accuracy: low susceptibility testing area the average recovery = 103%, gao min testing area the average recovery = 98%.
My company product of the clinical application of:
1, the early found heart failure patients,
2, detection of heart failure the therapeutic efficacy of drugs evaluation,
Three, the risk stratification of heart failure patients,
4, acute coronary syndrome risk assessment,
5, detection of heart failure treatment,
6, the cardiac the prognosis of heart failure patients,
7, distinguish between heart failure and other causes of difficulty breathing.
Recently, a clinical research: using NT-ProBNP assist in making the diagnosis congestive heart failure, the severity of the illness of the judgment and prognosis, and guide therapy has made the medical attention. It has been awarded as 2002 international medical ten big news, 2002 years is worth to pay close attention to ten big achievements of clinical medicine.
To date, there have been more than paper related research papers published in the New England journal of medicine (2002,347/3), circulation medical (2002105,-28), the American heart journal of (July 2002/2200 2-2009) other authoritative magazine. The paper discusses such as NT-ProBNP in heart failure emergency diagnosis function, rapid NT-ProBNP detection for difference of congestive heart failure or lung disease that causes breathing difficult problems, such as patients, for heart failure diagnosis and evaluation has opened up a whole new area.
N-end brain natriuretic peptide precursor is b-type natriuretic peptide hormones after the activity of the original split without the fragments N, mainly in the myocardial cells by load capacity increased by the left ventricular secretion, our company is mainly to a plant high specificity, high sensitivity NT-proBNP monoclonal antibodies for mark antibody, polyclonal antibody to capture antibody, combined with streptavidin-meal-biotin amplification system, the application of immune jinbiao chromatography technology. Detection of blood-proBNP NT, the content of which the patient diagnosis and screening, mainly is suitable for the instrument for nanjing perlong medical equipment Co., LTD. FIA8000 series immune quantitative analyzer.
My company product performance mainly for:
1, the double double control, and increase detecting window wide, and to improve the diagnostic value.
2, and some famous company of the same kind POCT products compare, the diagnosis window wide, price moderate, forgive by the domestic production line production, reliable quality, ensure that there is sufficient resources,
3, high sensitivity, the minimum detection is not higher than 100 pg/ml,
4, dose response curve of the linear correlation coefficient r > 0.990,
5, precision: of < 10%, within the CV of < 15%, between CV
6 and the accuracy: low susceptibility testing area the average recovery = 103%, gao min testing area the average recovery = 98%.
My company product of the clinical application of:
1, the early found heart failure patients,
2, detection of heart failure the therapeutic efficacy of drugs evaluation,
Three, the risk stratification of heart failure patients,
4, acute coronary syndrome risk assessment,
5, detection of heart failure treatment,
6, the cardiac the prognosis of heart failure patients,
7, distinguish between heart failure and other causes of difficulty breathing.
没有评论:
发表评论